Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
Protects the body from cellular damage caused by free radicals
GSTM1 and GSTP1, but not GSTT1 genetic polymorphisms are associated with chronic myeloid leukemia risk and treatment response
BPC-157: The Body Protection Compound The name reflects a focus on protection and recovery after tissue stress
Wolverine vs BPC-157 vs TB-500 vs Thymosin Alpha-1 Comparison Safety and Side Effects in Studies Most research on BPC-157, TB-500, and their combination has been conducted in preclinical animal models
Once oxidized, the solution has lost most of its bioactive potential and should be discarded
)
US$ 24.76
US$ 29.25
US$ 27.79
US$ 27.51
US$ 20.00
US$ 22.37
US$ 22.76
